In-Hospital Outcomes and Long-Term Follow-Up after Percutaneous Transcatheter Closure of Postinfarction Ventricular Septal Defects
Table 1
Demographic and clinical characteristics of the patients included in this study (N = 15). Patients who died during hospitalization were included in the death group, while those who survived were included in the survival group.
Survival (n = 11)
Death (n = 4)
P value
Age, years
0.269
Men, n (%)
5 (45.45)
1 (25.00)
0.604
Body mass index, kg/m2
0.883
Current smoker, n (%)
3 (27.27)
3 (75.00)
0.235
Hypertension, n (%)
7 (63.64)
2 (50.00)
0.538
Hyperlipidemia, n (%)
10 (91.00)
3 (75.00)
0.476
Diabetes, n (%)
2 (18.18)
1 (25.00)
0.774
Admission SBP, mm Hg
0.049
Admission DBP, mm Hg
0.013
Heart rates, beats/min
0.071
Shock, n (%)
1 (9.10)
3 (75.00)
0.033
Infarct territory, n (%)
Anterior
7 (63.64)
3 (75.00)
0.593
Inferior
4 (36.35)
1 (25.00)
0.593
Culprit lesion, n (%)
LAD
7 (63.64)
3 (75.00)
0.593
LCX
2 (18.18)
1 (25.00)
0.774
RCA
1 (9.10)
1 (25.00)
0.476
NYHA classification, n (%)
I
2 (18.18)
0 (0.00)
—
II
3 (27.27)
0 (0.00)
—
III
5 (45.45)
1 (25.00)
0.462
IV
1 (9.10)
3 (75.00)
0.033
LVEF, %
0.037
β-Receptor blocker, n (%)
6 (54.54)
2 (50.00)
0.662
ACEI/ARB, n (%)
7 (63.63)
2 (50.00)
0.538
Spironolactone, n (%)
7 (63.63)
3 (75.00)
0.593
Creatinine, μmol/L
0.502
Mean values (standard deviation) and total number (percentage) are given for continuous and categorical variables, respectively. SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker.
